Caitong International Asset Management Co. Ltd Boosts Holdings in Genmab A/S Sponsored ADR $GMAB

Caitong International Asset Management Co. Ltd boosted its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 200.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,809 shares of the company’s stock after purchasing an additional 3,878 shares during the quarter. Caitong International Asset Management Co. Ltd’s holdings in Genmab A/S were worth $120,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Headlands Technologies LLC lifted its stake in Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after purchasing an additional 1,464 shares in the last quarter. CWM LLC lifted its stake in Genmab A/S by 50.5% in the 2nd quarter. CWM LLC now owns 1,797 shares of the company’s stock worth $37,000 after purchasing an additional 603 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Genmab A/S by 377.5% in the 2nd quarter. Parallel Advisors LLC now owns 3,720 shares of the company’s stock worth $77,000 after buying an additional 2,941 shares during the last quarter. Brooklyn Investment Group increased its holdings in shares of Genmab A/S by 729.3% in the 1st quarter. Brooklyn Investment Group now owns 4,246 shares of the company’s stock worth $83,000 after buying an additional 3,734 shares during the last quarter. Finally, Advisors Preferred LLC bought a new position in shares of Genmab A/S in the 1st quarter worth $84,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on GMAB shares. Guggenheim raised shares of Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target on the stock in a report on Tuesday, September 23rd. Zacks Research raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 2nd. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of Genmab A/S in a report on Wednesday, October 15th. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Genmab A/S from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 18th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.80.

Genmab A/S Stock Performance

GMAB stock opened at $29.89 on Friday. Genmab A/S Sponsored ADR has a 52 week low of $17.24 and a 52 week high of $33.65. The firm’s fifty day moving average is $28.72 and its 200 day moving average is $23.72. The firm has a market cap of $19.19 billion, a P/E ratio of 15.02, a P/E/G ratio of 1.67 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million for the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.